Insider · CIK 0001571469

Countouriotis Athena

Reports to the SEC for 8 companies · SAN CARLOS, CA

sec.gov

Transactions

Companies

Filings

CIK

0001571469

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-16	IOVAIOVANCE BIOTHERAPEUTICS, INC. · Deferred Restricted Stock UnitA Award	Director	AAward	+90.3K sh	—	—	90,316
2026-06-02	BMRNBIOMARIN PHARMACEUTICAL INCA Award	Director	AAward	+7,490 sh	—	—	21,040
2026-05-19	PASGPassage BIO, Inc. · Director Stock Option (right to buy)A Award	Director	AAward	+10.5K sh	—	—	10,539
2025-06-13	IOVAIOVANCE BIOTHERAPEUTICS, INC. · Deferred Restricted Stock UnitA Award	Director	AAward	+67.5K sh	—	—	67,546
2025-05-28	PASGPassage BIO, Inc. · Director Stock Option (right to buy)A Award	Director	AAward	+202K sh	—	—	201,857
2025-05-20	BMRNBIOMARIN PHARMACEUTICAL INCA Award	Director	AAward	+6,650 sh	—	—	13,550
2024-06-11	IOVAIOVANCE BIOTHERAPEUTICS, INC. · Deferred Restricted Stock UnitA Award	Director	AAward	+49.3K sh	—	—	49,303
2024-05-21	BMRNBIOMARIN PHARMACEUTICAL INCA Award	Director	AAward	+4,720 sh	—	—	6,900
2024-05-21	PASGPassage BIO, Inc. · Director Stock Option (right to buy)A Award	Director	AAward	+47.7K sh	—	—	47,693
2024-03-01	IOVAIOVANCE BIOTHERAPEUTICS, INC. · Deferred Restricted Stock UnitA Award	Director	AAward	+50K sh	—	—	50,000
2023-12-27	BMRNBIOMARIN PHARMACEUTICAL INCA Award	Director	AAward	+2,180 sh	—	—	2,180
2023-06-06	IOVAIOVANCE BIOTHERAPEUTICS, INC. · Deferred Restricted Stock UnitA Award	Director	AAward	+52K sh	—	—	51,955
2023-05-25	PASGPassage BIO, Inc. · Director Stock Option (Right to Buy)A Award	Director	AAward	+24K sh	—	—	24,000
2022-08-17	Turning Point Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	Director, President & CEO	DDisposition to Issuer	−325K sh	—	—	0
2022-08-17	Turning Point Therapeutics, Inc.D Disposition to Issuer	Director, President & CEO	DDisposition to Issuer	−111K sh	$76.00	−$8.43M	0
2022-08-17	Turning Point Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	Director, President & CEO	DDisposition to Issuer	−173K sh	—	—	0
2022-08-17	Turning Point Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	Director, President & CEO	DDisposition to Issuer	−67.6K sh	—	—	0
2022-08-17	Turning Point Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	Director, President & CEO	DDisposition to Issuer	−990K sh	—	—	0
2022-08-17	Turning Point Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	Director, President & CEO	DDisposition to Issuer	−156K sh	—	—	0
2022-08-17	Turning Point Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	Director, President & CEO	DDisposition to Issuer	−102K sh	—	—	0
2022-08-17	Turning Point Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	Director, President & CEO	DDisposition to Issuer	−225K sh	—	—	0
2022-06-10	IOVAIOVANCE BIOTHERAPEUTICS, INC. · Deferred Restricted Stock UnitA Award	Director	AAward	+51.2K sh	—	—	51,204
2022-05-26	PASGPassage BIO, Inc. · Director Stock Option (Right to Buy)A Award	Director	AAward	+24K sh	—	—	24,000
2022-02-09	Turning Point Therapeutics, Inc.S Sale	Director, President & CEO	SSale	−2,971 sh	$36.30	−$108K	47,930
2022-02-09	Turning Point Therapeutics, Inc.A Award	Director, President & CEO	AAward	+62.4K sh	—	—	110,330
2022-02-09	Turning Point Therapeutics, Inc.Stock Option (right to buy)A Award	Director, President & CEO	AAward	+225K sh	—	—	224,640
2021-06-29	IOVAIOVANCE BIOTHERAPEUTICS, INC. · Stock Option (right to buy)A Award	Director	AAward	+35K sh	—	—	35,000
2021-05-27	PASGPassage BIO, Inc. · Director Stock Option (Right to Buy)A Award	Director	AAward	+16.9K sh	—	—	16,918
2021-02-11	Turning Point Therapeutics, Inc.S Sale	Director, President & CEO	SSale	−4,319 sh	$136.45	−$589K	54,818
2021-02-11	Turning Point Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	−8,942 sh	—	—	173,389
2021-02-11	Turning Point Therapeutics, Inc.M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	+8,942 sh	$3.20	+$28.6K	59,137
2021-02-11	Turning Point Therapeutics, Inc.S Sale	Director, President & CEO	SSale	−1,571 sh	$137.66	−$216K	53,247
2021-02-11	Turning Point Therapeutics, Inc.S Sale	Director, President & CEO	SSale	−3,052 sh	$138.55	−$423K	50,195
2021-02-10	Turning Point Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	−25.4K sh	—	—	182,331
2021-02-10	Turning Point Therapeutics, Inc.M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	+25.4K sh	$3.20	+$81.3K	75,587
2021-02-10	Turning Point Therapeutics, Inc.S Sale	Director, President & CEO	SSale	−1,025 sh	$134.34	−$138K	74,562
2021-02-10	Turning Point Therapeutics, Inc.S Sale	Director, President & CEO	SSale	−5,227 sh	$135.72	−$709K	69,335
2021-02-10	Turning Point Therapeutics, Inc.S Sale	Director, President & CEO	SSale	−16.6K sh	$136.42	−$2.27M	52,709
2021-02-10	Turning Point Therapeutics, Inc.S Sale	Director, President & CEO	SSale	−2,081 sh	$137.46	−$286K	50,628
2021-02-10	Turning Point Therapeutics, Inc.S Sale	Director, President & CEO	SSale	−433 sh	$138.19	−$59.8K	50,195
2021-02-09	Turning Point Therapeutics, Inc.M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	+7,666 sh	$3.20	+$24.5K	75,861
2021-02-09	Turning Point Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	−18K sh	—	—	207,723
2021-02-09	Turning Point Therapeutics, Inc.S Sale	Director, President & CEO	SSale	−1,104 sh	$140.24	−$155K	50,195
2021-02-09	Turning Point Therapeutics, Inc.S Sale	Director, President & CEO	SSale	−13.3K sh	$139.69	−$1.86M	51,299
2021-02-09	Turning Point Therapeutics, Inc.S Sale	Director, President & CEO	SSale	−4,969 sh	$138.66	−$689K	64,589
2021-02-09	Turning Point Therapeutics, Inc.S Sale	Director, President & CEO	SSale	−103 sh	$137.58	−$14.2K	69,558
2021-02-09	Turning Point Therapeutics, Inc.S Sale	Director, President & CEO	SSale	−6,200 sh	$136.29	−$845K	69,661
2021-02-09	Turning Point Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	−7,666 sh	—	—	67,575
2021-02-09	Turning Point Therapeutics, Inc.M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	+18K sh	$3.20	+$57.6K	68,195
2021-02-08	Turning Point Therapeutics, Inc.A Award	Director, President & CEO	AAward	+22.6K sh	—	—	50,195

Recent filings

Accepted (ET)
Jun 184
Countouriotis Athena0001104659-26-075858
SEC(opens sec.gov)
Jun 44
Countouriotis Athena0001628280-26-040922
SEC(opens sec.gov)
May 214
Countouriotis Athena0001571469-26-000002
SEC(opens sec.gov)
Jun 174
Countouriotis Athena0001104659-25-060254
SEC(opens sec.gov)
May 304
Countouriotis Athena0001415889-25-015058
SEC(opens sec.gov)
May 224
Countouriotis Athena0001048477-25-000066
SEC(opens sec.gov)
Jun 134
Countouriotis Athena0001104659-24-071374
SEC(opens sec.gov)
May 234
Countouriotis Athena0001415889-24-014333
SEC(opens sec.gov)
May 234
Countouriotis Athena0001048477-24-000096
SEC(opens sec.gov)
Mar 54
Countouriotis Athena0001104659-24-031105
SEC(opens sec.gov)
Dec 284
Countouriotis Athena0001048477-23-000068
SEC(opens sec.gov)
Jun 84
Countouriotis Athena0001104659-23-069509
SEC(opens sec.gov)
May 264
Countouriotis Athena0001209191-23-032542
SEC(opens sec.gov)
Aug 174
Countouriotis Athena0001209191-22-046258
SEC(opens sec.gov)

Companies

Address

C/O IOVANCE BIOTHERAPEUTICS, INC. 825 INDUSTRIAL ROAD, SUITE 100

SAN CARLOS, CA, 94070